by barry101 | Mar 25, 2022 | Press Releases
– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine – – Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute...
by barry101 | Mar 23, 2022 | Press Releases
HOUSTON, March 23, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Mar 11, 2022 | Press Releases
Presentation with live webcast on Thursday, March 17th at 9:20 AM ETHOUSTON, March 11, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug...
by barry101 | Mar 1, 2022 | Press Releases
– Biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with successful track record leading development of multiple oncology products from strategic planning through global submissions and...
by barry101 | Feb 14, 2022 | Press Releases
– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine- Phase 1 study sets a recommended Phase 2 dose of 240 mg/m², enabling start of combination trial-...
by barry101 | Jan 20, 2022 | Press Releases
– Live video webcast presentation on Thursday, January 27th at 9:00 AM ET -HOUSTON, Jan. 20, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
